1、Rubicon 14 支撐(zh chng)導(dǎo)管共十九頁(yè)UnderstandingChronic Total Occlusions Clinical Overview看看慢性(mn xng)全閉塞病變的情況共十九頁(yè)CTO-慢性(mn xng)全閉塞性病變臨床需求CTOs在下肢手術(shù)中的發(fā)病約為30-40%；將近40%的CTO需要多種技術(shù)以穿越病變1新技術(shù)的發(fā)展推動(dòng)了血管腔內(nèi)治療的CTO治療2 沒(méi)有CTO治療的金標(biāo)準(zhǔn)(biozhn)3 多種治療方案實(shí)驗(yàn)性及錯(cuò)誤的方法器械選擇決定于熟練程度和使用的便利性主要挑戰(zhàn)產(chǎn)品表現(xiàn)不佳和臨床效果不佳器械外廓大，精確度有限，學(xué)習(xí)曲線(xiàn)長(zhǎng)額外的手術(shù)時(shí)間和復(fù)雜性1. 2

2、010-2011 Global PI Tracking Study; 2. True lumen re-entry devices facilitate subintimal angioplasty and stenting of CTOs Jacobs, D., et al, Journal of Vasc Surgery, Jun 2006 3. PI MAB 2011 Feedback共十九頁(yè)CTO解剖(jipu)大部分SFA長(zhǎng)段閉塞，通常可以在造影下看到近端像樹(shù)樁一樣的頭端，然后遠(yuǎn)端血管不同程度顯影(xin yng)，或來(lái)自股深動(dòng)脈的側(cè)支。Crossing Peripheral CTO

3、s. Tony S. Das, MD. Endovascular Today, March 2006Results from case studies are not predictive of results in other cases. Results in other cases may vary.共十九頁(yè)嚴(yán)重肢體缺血(CLI)患者(hunzh)的臨床考量共十九頁(yè)CLI不僅僅只是(zhsh)針對(duì)BTKCLI不僅僅是由BTK血管病變引起的，為了重建足部的血運(yùn)，我們需要考慮整個(gè)下肢的血管狀況流入道病變 主要是在SFA，也有在髂動(dòng)脈. (CLI累及髂動(dòng)脈少見(jiàn)，如累及髂動(dòng)脈時(shí)多數(shù)患者會(huì)有嚴(yán)重的

4、間歇性跛行)流出道病變 主要是在脛動(dòng)脈和腓動(dòng)脈，但通常擴(kuò)展至足部動(dòng)脈一個(gè)417例患者的研究表明，每位患者在膝關(guān)節(jié)和足部之間的血管平均(pngjn)有6.9個(gè)病灶共十九頁(yè)病灶(bngzo)分布Vascular Involvement in Diabetic Subjects with Ischemic Foot Ulcer: A New Morphologic Categorization of Disease SeverityL. Graziani et al. Eur J Vasc Endovasc Surg 33, 453e460 (2007)共十九頁(yè)BTK閉塞最為常見(jiàn)，但SFA的病變更值

5、得(zh d)關(guān)注Lesion Distribution (417 patients, 2893 lesions)共十九頁(yè)無(wú)法穿越(chun yu)? 無(wú)法治療! 穿刺和穿越病變是最令人沮喪(jsng)，最耗時(shí)的！如果你無(wú)法到達(dá)和穿越病變，就無(wú)法進(jìn)行治療！共十九頁(yè)RubiconTM 14支撐(zh chng)導(dǎo)管共十九頁(yè)Rubicon 14-產(chǎn)品(chnpn)參數(shù)All cited trademarks are the property of their respective owners. CAUTION: The law restricts these devices to sale by

6、 or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device. Information for the use only in countries with applicable health authority product registrations.共十九頁(yè)Rubicon 14支撐導(dǎo)管突破(tp)強(qiáng)硬病變超低的頭端通過(guò)外廓幫助通

7、過(guò)復(fù)雜(fz)病變強(qiáng)硬的遠(yuǎn)端頭端和桿身材料提供優(yōu)秀的推送性三個(gè)不透射線(xiàn)標(biāo)記點(diǎn)提供優(yōu)秀的可視性共十九頁(yè)0.018” (0.46 mm) 頭端通過(guò)外廓新一代尼龍頭端和桿身材料三個(gè)不透射線(xiàn)標(biāo)記點(diǎn)對(duì)比明顯的紫色頭端透明接頭(ji tu)和近端桿身材料遠(yuǎn)端親水涂層135 cm和150cm長(zhǎng)度提高復(fù)雜病變進(jìn)入和通過(guò)性加強(qiáng)推送性，提高 病變通過(guò)性能優(yōu)秀的可視性更易辨識(shí)，簡(jiǎn)化導(dǎo)絲的裝載(zhungzi)提高血流回滲的可視性？提高通過(guò)性多種長(zhǎng)度選擇，適用于近端及遠(yuǎn)端病變Rubicon 14支撐導(dǎo)管關(guān)鍵特性與利益利益特性 共十九頁(yè)Rubicon 14支撐(zh chng)導(dǎo)管產(chǎn)品定位突破(tp)強(qiáng)硬病變Tackl

8、e Tougher LesionsRubicon 14支撐導(dǎo)管促進(jìn)/提高致密或閉塞性病變的通過(guò)-Facilitates crossing of tight occlusions.0.018”的頭端通過(guò)外廓，強(qiáng)硬的新一代遠(yuǎn)側(cè)頭端技術(shù)提供了優(yōu)秀的推送能力，加上三個(gè)不透射線(xiàn)標(biāo)記點(diǎn)，使得Rubicon具有卓越的病變通過(guò)性為你在應(yīng)對(duì)致密或閉塞病變時(shí)提供最大的幫助！共十九頁(yè)CXITM Support Catheter-COOK0.018”及0.035”系統(tǒng)90,135,150cm三種長(zhǎng)度可供選擇直頭和彎頭兩種頭端形狀桿身3個(gè)，頭端1個(gè)，共4個(gè)不透射線(xiàn)(shxin)標(biāo)記點(diǎn)遠(yuǎn)端40cm桿身有親水涂層桿身金屬編

9、織結(jié)構(gòu)價(jià)格：RMB5000共十九頁(yè)TrailBlazer Support Catheter-Covidien0.014”,0.018”及0.035”系統(tǒng)65,90,135,150cm工作(gngzu)長(zhǎng)度直頭頭端外廓：0.035”系統(tǒng)-0.040”0.018”系統(tǒng)-0.022”0.014”系統(tǒng)-0.019”三個(gè)不透射線(xiàn)標(biāo)記點(diǎn)遠(yuǎn)端40cm親水涂層價(jià)格：RMB3000+共十九頁(yè)Rubicon 14支撐(zh chng)導(dǎo)管更好的推送性Average measurements taken by Boston Scientific. N = 10. Data on file. Bench test r

10、esults may not necessarily be indicative of clinical performance.Push is defined as a measure of the shafts ability to transmit force to distal tip in straight-line configuration. All cited trademarks are the properties of their respective owners. TrailBlazer TM is a registered trademark of ev3. Qui

11、ck Cross is a product owned by Spectranetics; Minnie is a product owned by Vascular solutions.共十九頁(yè)Rubicon 14支撐導(dǎo)管(dogun)超低的頭端通過(guò)外廓Average measurements taken by Boston Scientific. N = 10. Data on file. Bench test results may not necessarily be indicative of clinical performance.共十九頁(yè)內(nèi)容摘要Rubicon 14 支撐導(dǎo)管。流出道病變 主要是在脛動(dòng)脈和腓動(dòng)脈，但通常擴(kuò)展至足部動(dòng)脈。如果(